| Literature DB >> 32434947 |
Yann Kieffer1,2, Hocine R Hocine1,2, Géraldine Gentric1,2, Floriane Pelon1,2, Charles Bernard1,2, Brigitte Bourachot1,2, Sonia Lameiras3, Luca Albergante4,5, Claire Bonneau1,2,6, Alice Guyard7, Karin Tarte8, Andrei Zinovyev4,5, Sylvain Baulande3, Gerard Zalcman1,2,9, Anne Vincent-Salomon10, Fatima Mechta-Grigoriou11,2.
Abstract
A subset of cancer-associated fibroblasts (FAP+/CAF-S1) mediates immunosuppression in breast cancers, but its heterogeneity and its impact on immunotherapy response remain unknown. Here, we identify 8 CAF-S1 clusters by analyzing more than 19,000 single CAF-S1 fibroblasts from breast cancer. We validate the five most abundant clusters by flow cytometry and in silico analyses in other cancer types, highlighting their relevance. Myofibroblasts from clusters 0 and 3, characterized by extracellular matrix proteins and TGFβ signaling, respectively, are indicative of primary resistance to immunotherapies. Cluster 0/ecm-myCAF upregulates PD-1 and CTLA4 protein levels in regulatory T lymphocytes (Tregs), which, in turn, increases CAF-S1 cluster 3/TGFβ-myCAF cellular content. Thus, our study highlights a positive feedback loop between specific CAF-S1 clusters and Tregs and uncovers their role in immunotherapy resistance. SIGNIFICANCE: Our work provides a significant advance in characterizing and understanding FAP+ CAF in cancer. We reached a high resolution at single-cell level, which enabled us to identify specific clusters associated with immunosuppression and immunotherapy resistance. Identification of cluster-specific signatures paves the way for therapeutic options in combination with immunotherapies.This article is highlighted in the In This Issue feature, p. 1241. ©2020 American Association for Cancer Research.Entities:
Year: 2020 PMID: 32434947 DOI: 10.1158/2159-8290.CD-19-1384
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397